NCT05942599View on ClinicalTrials.gov

Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Relapsed Acute Myeloid Leukaemia
Interventions
BIOLOGICAL

Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)

Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months

Trial Locations (1)

WC1N3JH

RECRUITING

Great Ormond Street Hospital for Children, London

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

lead

Great Ormond Street Hospital for Children NHS Foundation Trust

OTHER